Introduction
The role of estrogen receptor-a (ER) in normal breast development and in breast cancer is well established (Osborne, 1998) . For breast cancer treatment, ER status is of paramount importance for the selection of appropriate hormonal therapy and as a prognostic marker. At presentation, over 75% of breast tumors are ER-positive and are treated with targeted anti-estrogen therapy, such as the selective estrogen receptor modulators tamoxifen and raloxifene (Osborne et al., 2000; Herynk and Fuqua, 2007) , as well as the selective estrogen receptor down-regulator fulvestrant (Faslodex, ICI 182, 780) (Osborne et al., 2004) . Recently, the aromatase inhibitors letrozole, exemestane, and anastrozole, that directly target the production of estrogen from testosterone are increasingly being used in the clinic (Osborne and Schiff, 2005; Osborne and Tripathy, 2005) . These inhibitors are more effective and demonstrate fewer side effects when compared with tamoxifen, which is the most commonly prescribed anti-estrogen drug (Herynk and Fuqua, 2007) . In contrast, ERnegative tumors are refractory to anti-estrogen therapy from the onset and are associated with a poor clinical prognosis (Herynk and Fuqua, 2007) . In addition, a majority of ER-positive breast tumors become hormone resistant through various mechanisms and patients suffer relapse within 5 years Herynk and Fuqua, 2007) . Epigenetic silencing through promoter hypermethylation of ER accounts for a major portion of ER gene silencing (Ottaviano et al., 1994; Yan et al., 2001) . Mutations within the ER gene are observed in about 1% of primary breast tumors, but it is unclear how these contribute to the regulation of ER expression (Roodi et al., 1995; Murphy et al., 1997; Fuqua et al., 2000; Herynk and Fuqua, 2004) . In addition to these regulatory mechanisms, ER is also regulated transcriptionally (deConinck et al., 1995; Angeloni et al., 2004) . Changes in proliferation and apoptotic stimuli, including ER and cyclin D1 signaling, contribute to tumor homeostasis (Herynk and Fuqua, 2007) , and to the activation of classical signaling pathways, such as HER-2 and EGFR (Herynk and Fuqua, 2007) , MAPK (Oh et al., 2001) , and PI3K/AKT (Campbell et al., 2001) , all of which have also been implicated in hormone resistance. TWIST1 (Twist) is a basic helix-loop-helix transcription factor involved in the negative regulation of cellular determination (Rose and Malcolm, 1997) and in the differentiation of several lineages, including myogenesis and osteogenesis (Hebrok et al., 1997; Bialek et al., 2004) . Twist is overexpressed in breast cancers , promotes chromosomal instability (Vesuna et al., 2006) , regulates the tumor suppressor protein E-cadherin (CDH1) (Vesuna et al., 2008) and p53 (Stasinopoulos et al., 2005) , and promotes the generation of breast cancer stem cells (Vesuna et al., 2009) . However, its mechanistic role in breast cancer progression is still not completely understood.
In this study, we identified ER as a target of Twist by demonstrating that Twist binds to the ER promoter and downregulates its transcription. This is accompanied by de novo methylation of the ER promoter that is caused by recruitment of DNA methyltransferase 3B (DNMT3B). Twist also mobilizes histone deacetylase 1 (HDAC1), which suppresses ER expression due to the formation of a repressive chromatin structure caused by deacetylation of the ER promoter. Both these effects can be partially reversed by using the methylation-inhibiting reagent, 5-azacytidine (AZA), and the HDAC inhibitor, valproic acid (VPA). Functionally, the loss of ER in breast cancer cells overexpressing Twist results in hormonal independence and resistance to the antiestrogens, tamoxifen and fulvestrant. Moreover, Twistoverexpressing breast cancer cells are able to form orthotopic tumors in severe combined immunodeficient mice in the absence of estrogen supplementation. Furthermore, these tumors have a high vascular volume (VV) and high vascular permeability. Finally, we show an inverse correlation between Twist and ER expression in human breast tumors. Taken together, these data suggest a mechanistic link between the upregulation of Twist and the loss of ER, which leads to the progression of ER-negative and hormone-resistant breast cancer.
Results

ER is downregulated in Twist-overexpressing breast cancer cell lines
To characterize the role of Twist in breast cancer biogenesis, we initially analyzed the MCF-7/Twist cell line for differential gene expression using microarray analysis (Affymetrix, Santa Clara, CA, USA), and identified the ER transcript, which was downregulated by 13-fold. To confirm this finding, breast cancer cell lines were evaluated for Twist and ER expression by immunoblotting and quantitative reverse transcriptase (qRT)-PCR. As shown in Figures 1a and b , there was an inverse correlation between Twist and ER protein and mRNA levels within the cell lines tested.
Twist represses ER promoter activity in breast cancer cells
To functionally confirm the regulatory role of Twist in ER downregulation, we performed promoter-reporter assays in breast cancer cell lines. The 4-kb ER promoter has 26 canonical E-box sequences (CANNTG) (Murre et al., 1989) to which Twist can potentially bind ( Figure 1c ). Transient transfections with Twist plasmids were carried out for promoter reporter assays in MCF-7 ( Figure 1c ) and MCF-7/Twist cells (data not shown). Twist repressed the full-length ER promoter by 2.5-fold, whereas the other deletion constructs were repressed from 2.5-to 3-fold.
In order to confirm the role of the bHLH regions of Twist in binding the ER promoter, we used the fulllength ER promoter and Twist bHLH deletion mutants to assay for ER promoter repression. As seen in Figure 1d , none of the Twist mutants demonstrated repression comparable to wild-type Twist, except for the deletion mutant Q161X, which was downstream of the bHLH domain.
Twist binds directly to E-boxes within the ER promoter
To address the question of whether Twist binds directly to the ER promoter, we performed chromatin immunoprecipitation (ChIP) assays using MCF-7/Twist and MDA-MB-231 cell lines (Figures 1e-f ). MDA-MB-231 is an ER-negative breast cancer cell line with high levels of endogenous Twist. ChIP was carried out as per instructions (Cell Signaling, Danvers, MA, USA) using antibodies against Twist. Normal rabbit immunoglobulin G was used as a negative control, whereas Histone H3 was used as a positive control antibody. Five pairs of primers were designed to span the ER promoter and the 26 putative Twist-binding E-boxes ( Figure 1c ). Maximum ChIP binding was seen in the areas of E-box 6-9 in MCF-7/Twist and MDA-MB-231 cells. Significant binding was also seen in the area of E-boxes 16-17 in MCF-7/Twist cells. These results indicate that Twist binds directly or as part of a complex to the endogenous ER promoter.
Twist facilitates estrogen independence in breast cells
As we observed increased Twist expression in ERnegative cell lines, we sought to determine whether Twist promoted hormone independence by repressing ER expression. To confirm this observation, MCF-7 (ER-positive) and MCF-7/Twist (ER-negative) cells were grown for 3 days in estrogen-depleted media containing 5% charcoal-stripped serum (CSS), and cell cycle distribution was analyzed by flow cytometry (Figure 2 ). Proliferation of MCF-7 cells was significantly Twist regulates estrogen receptor-a expression in breast cancer reduced in CSS (S ¼ 5.4%) compared with untreated cells (S ¼ 15.6%, Po0.05) (Figure 2a ), but not in MCF-7/Twist cells (S ¼ 22.0 vs 19.5%, P40.05) ( Figure 2b) . Moreover, the percentages of cells in all three phases of the cell cycle was significantly altered between MCF-7 and MCF-7/Twist cells treated with CSS: G1 ¼ 85.2 vs 63.2%, Po0.05; S ¼ 5.4 vs 22.0%, Po0.005; and G2 ¼ 6.3 vs 12.1%, Po0.05 ( Figure 2c) . The difference was insignificant in the untreated controls of both MCF-7 and MCF-7/Twist. These results support our earlier data indicating that the downregulation of ER by Twist in MCF-7 cells leads to estrogen-independent growth. Twist regulates estrogen receptor-a expression in breast cancer F Vesuna et al
Twist promotes hormone resistance in breast cancer cells
To determine whether the loss of ER brought about by Twist caused hormone resistance in breast cancer cells, we treated MCF-7 and MCF-7/Twist cells with the selective estrogen receptor modulator, tamoxifen, and the selective estrogen receptor down-regulator, fulvestrant. As seen in Figure 2d , MCF-7 cells were significantly arrested in the presence of tamoxifen (S ¼ 2.3%) compared with untreated cells (S ¼ 15.6%, Po0.005). However, MCF-7/ Twist cells were largely unaffected by tamoxifen treatment (S ¼ 16.6 vs 19.5%, P40.05) (Figure 2e ). In addition, the G1 and S phases of the cell cycle were significantly altered in MCF-7 and MCF-7/Twist cells treated with tamoxifen (G1 ¼ 86.6 vs 66.5%, Po0.005; S ¼ 2.3 vs 16.6%, Po0.005; G2 ¼ 8.9 vs 14.2%, P40.05) ( Figure 2f ). Treatment with fulvestrant exhibited results comparable to those of tamoxifen. MCF-7 cell growth was significantly affected by treatment (S ¼ 3.9%), compared with untreated controls (S ¼ 15.6%, Po0.005) (Figure 2g ), whereas MCF-7/Twist cells were unaffected by the treatment (S ¼ 16.6 vs 19.5%, P40.05) (Figure 2h ). Similarly, MCF-7 cells were significantly affected by the fulvestrant treatment compared with MCF-7/Twist cells (G1 ¼ 86 vs 67.7%, Po0.005; S ¼ 3.9 vs 16.6%, Po0.0005; G2 ¼ 5.8 vs 13.3%, Po0.05) (Figure 2i ). There were no significant differ-ences in cell cycle phases for untreated MCF-7 and MCF-7/Twist (data not shown).
Hormone resistance is reversed by down regulation of Twist in breast cancer cells
To determine whether the loss of Twist caused a reversion to the estrogen-dependent, hormone-sensitive phenotype, we downregulated Twist expression in MCF-7/Twist and MDA-MB-231 cells using a lentiviral-delivered shRNA-based approach. As seen in Figures 3a-c, MCF-7/Twist shTwist cells showed significantly higher cell death after growth in CSS or on exposure to tamoxifen compared with parental MCF-7/Twist cells, which remained unaffected. Similar effects were also seen in MDA-MD-231 shTwist cells (Figures 3d-f ). This would indicate that the ER independence and hormone resistance exhibited by MCF-7/Twist and MDA-MB-231 cells is, at least partially, due to Twist expression and can be reversed by downregulation of Twist.
Twist promotes the growth of breast tumors in the absence of estrogen To strengthen our finding that overexpression of Twist induced estrogen independence in vivo, we orthotopi- (Fox, 1980) . Experiments were independently repeated four times.
Twist regulates estrogen receptor-a expression in breast cancer F Vesuna et al cally injected MCF-7/Twist cells into the mammary fat pads of severe combined immunodeficient mice, which were not supplemented with estrogen. As seen in Figure 4a , MCF-7/Twist xenografts produced large tumors (greater 4250 mm 3 ) within 4 to 5 weeks of incubation. These results confirmed that MCF-7/Twist cells are estrogen independent in vivo. In order to confirm that the expression of Twist and ER in tumors was similar to that in MCF-7/Twist cells, we isolated RNA from four tumors and performed qRT-PCR using Twist and ER primers. As seen in Figure 4b , the expression of Twist was inversely correlated with the levels of ER transcripts. Next, we injected mice (n ¼ 10) with MCF-7/Twist and MCF-7 cells in the presence of estrogen (a 17bestradiol pellet implanted in the back). After 3-4 weeks of growth, all mice were implanted with a tamoxifen pellet. As seen in Figures 4c-d , MCF-7 tumors regressed to pre-treatment levels, whereas MCF-7/Twist tumors were unaffected by tamoxifen.
Twist increases VV and vascular permeability of breast tumors in mice Functional magnetic resonance imaging was used to non-invasively analyze the VV and permeability-surface (PS) area product values in vivo. Figures 4e-f display representative false color-coded, magnetic resonance imaging-generated 3-D transverse slices of mice xenograft tumors using MCF-7 and MCF-7/Twist cells. The average tumor VV in MCF-7 ( þ estrogen) (E2) and MCF-7/Twist (ÀE2) xenografts was 6.2 and 14.9 ml/g, respectively (Figure 4e ). The average tumor PS in MCF-7 ( þ E2) and MCF-7/Twist (ÀE2) xenografts was 0.66 and 1.60 ml/g per min, respectively (Figure 4f ). Both these sets of results were significant (Scheffe's test, F ¼ 15.9 and 7.04, respectively). VV and PS values in MCF-7 vector control xenografts were comparable to those in MCF-7 xenografts (data not shown), and were consistent with the previous report . VV and PS in MCF-7/Twist ( þ E2) xenografts were 21.1 ml/g and 1.66 ml/g per min, respectively. These values were significantly higher than those in MCF-7 ( þ E2) controls (F ¼ 5.48 and 6.23, respectively). There was no significant difference between estrogen-supplemented and non-supplemented MCF-7/Twist xenografts for VV and PS (F ¼ 3.00 and 0.03, respectively).
Twist downregulation causes re-expression of ER To investigate the mechanism of ER regulation by Twist, we transiently downregulated Twist in MCF-7/ Twist cells and upregulated Twist in MCF-7 and T-47D. As seen in Figures 5a and b, downregulation of Twist in MCF-7/Twist cells caused a significant drop in mRNA levels of Twist accompanied by an increase in ER expression. The transient expression of Twist, however, caused a significant drop in ER protein in MCF-7 and T-47D cells (Figure 5c ). We also demonstrated that Her-2/neu protein levels were low in MCF-7/Twist cells, which indicates that the effect of Twist on ER was not mediated by Her-2/neu ( Supplementary Figure 1) . Furthermore, we determined that the reactivation of ER in the Twist-downregulated clones was functionally active. For this purpose, the ERE-luc construct was used as a functional reporter system (kind gift of Nancy Davidson) for the in vitro studies. As seen in Figure 5d , MCF-7/Twist cells show a significant drop in the activation of the reporter, indicating the lack of ER functionality in these cells. Importantly, the re-expression of ER by downregulating Twist in MCF-7/Twist cells increased reporter activity, an indication of functional ER proteins.
To further characterize the functionality of Twistmediated ER loss in breast cancer cells, we performed quantitative real-time PCR and immunoblotting for the downstream targets of ER, such as Cyclin D1, p21, p27 (Foster and Wimalasena, 1996) , p14 (Cho et al., 2006) , and Cathepsin D (Morisset et al., 1986) in MCF-7, MCF-7/Twist and MCF-7/Twist shTwist cells. Furthermore, we also probed for intrinsic levels of ER target genes in MCF-7 and MCF-7/Twist cells. As seen in Figure 5g , all the ER target genes were downregulated in MCF-7/Twist cells. This suggests that overexpression of Twist, in this system, can repress ER levels, which, in turn, affects the expression of its downstream target genes.
Twist induces hyper-methylation of the ER promoter A common mechanism of ER, gene silencing is that of promoter hypermethylation, which occurs in 5-49% of patient samples (Ottaviano et al., 1994; Yan et al., 2001) . Indeed, we did find a significant increase in ER promoter methylation in MCF-7/Twist cells, as observed by methylation-specific-qPCR analysis (Figure 5h ). Subsequently, we used cell lines with transiently up and downregulated Twist to validate our earlier observations. As seen in Figure 5i , Twist overexpression in T-47D cells caused an increase in ER promoter methylation. Notably, Twist downregulation in MCF-7/ Twist and MDA-MB-231 caused a significant decrease in ER promoter methylation. In order to reverse the Twist-induced methylation of the ER promoter, we treated MCF-7/Twist cells with the demethylating agent AZA. We found a significant increase in ER transcript and protein levels as seen by qRT-PCR and immunoblotting (Figures 5j-k) . Figure 4 In vivo growth characteristics of MCF-7 and MCF-7/Twist cells. (a) Line chart showing growth of 1 Â 10 6 MCF-7 cells (without E2, solid triangles; with E2, hollow circles) and MCF-7/Twist cells (without E2, solid squares) orthotopically implanted into female severe combined immunodeficient mice and allowed to grow for the time indicated. Tumors were measured weekly. (b) MCF-7/ Twist tumors from mice (n ¼ 4) were excised and Twist and ER transcript levels determined by qRT-PCR. The graph depicts relative differences in Twist and ER transcript levels. (c, d) Growth over 8 weeks of MCF-7 and MCF-7/Twist tumors treated with tamoxifen. Tamoxifen pellet implantation is indicated by an arrow. (e, f) Representative false color-coded, magnetic resonance imaging-generated 3-D transverse slices of MCF-7 and MCF-7/Twist xenografts in the mammary fat pad. Red and green represent the distributions of VV and vascular PS area product, respectively. Gray-scale images represent the mouse body; whereas tumors are seen on top and indicated by the 'T'. Averaged values from all mice are indicated in the figures, as well as displayed on the histograms at the right. Images depicted are a representative sample of five mice for MCF-7( þ E2), six mice for MCF-7/Twist(ÀE2) and six mice for MCF-7/Twist ( þ E2).
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To determine the mechanistic cause of the increased methylation of ER induced by Twist, we investigated the recruitment of DNA methyltransferases. The de novo methyltransferase DNMT3B was co-immunoprecipitated with Twist from MCF-7/Twist lysates (Figure 5l ). Other methyltransferases, such as DNMT1 Twist regulates estrogen receptor-a expression in breast cancer F Vesuna et al and DNMT3A, were not co-immunoprecipitated by Twist (data not shown).
Twist causes histone deacetylation of the ER promoter
Regulation of genes via methylation is accompanied, in some cases, by an increase in HDAC activity (Cameron et al., 1999) . Mechanistically, we determined that Twist recruited the HDAC HDAC1 (Figure 5l ) to the ER promoter, leading to deacetylation, which resulted in lowered expression of ER. In order to functionally study the role of HDACs in the regulation of ER, we treated MCF-7/Twist cells with the HDAC inhibitor VPA. As seen in Figure 5k , we found a significant increase in ER expression in these cells when treated with the inhibitor. The use of AZA and VPA in combination was able to rescue ER to a greater degree than either of them alone.
Twist recruits HDAC1 and DNMT3B to the ER promoter
In order to confirm our co-immunoprecipitation results, we performed ChIP experiments on MDA-MB-231 cells using HDAC1 and DNMT3B antibodies. As seen in Figure 5m , DNMT3B was recruited to all the E-box sites of the ER promoter, whereas HDAC1 was significantly recruited to E-box 6-9. Taken together, the largest enrichment of DNMT3B and HDAC1 binding was in the E-box 6-9 regions. This would point to an important role for the E-box 6-9 region in the regulation of ER by Twist via the interaction with HDAC1 and DNMT3B.
Twist and ER are inversely correlated in breast cancer patients
To further validate the inverse correlation between Twist and ER expression seen in breast cancer cell lines, Twist and ER mRNA levels in human breast tumors were quantified by qRT-PCR. A total of 73 primary breast cancers (grade 1, n ¼ 16; grade 2, n ¼ 22; grade 3, n ¼ 35) and 4 normal breast samples were analyzed ( Figure 6 ). We examined the correlation in normalized (to normal breast tissue) expression between Twist and ER genes, overall, and within each grade, using the nonparametric, Spearman rank test. Twist expression levels were significantly different from ER levels (Figure 6a ). We also observed an increase in Twist expression levels with increasing tumor grade, whereas ER expression levels showed a decrease with increasing tumor grade for grades 1 and 2. An inverse relation was observed with increased Twist expression associated with decreased ER expression, which was statistically significant in grades 1 and 2 (Figure 6b ), but not in grade 3 (Figure 6c ). Overall, these results suggest that Twist expression inversely correlates with ER expression in human breast cancers of grades 1 and 2.
Discussion
The regulation of ER has been a topic of interest for numerous investigators, given its importance in the development of breast tumors. The classification of breast tumors as either ER-positive or ER-negative has a significant impact on the selection of appropriate chemotherapeutic regimens, and a loss of ER has been correlated with a poor prognosis, in part, due to the exclusion of targeted anti-hormonal therapy. It has been well-established that a combination of genetic, epigenetic and transcriptional controls regulate ER expression. However, the ontogeny of tumor progression that leads to the formation of the ER-negative and/or estrogen resistant state is still not clearly understood.
In the present study, we have demonstrated that the transcriptional regulation of ER can be modulated by Twist, a protein that has been shown to be upregulated in high-grade breast cancer phenotypes . This finding was corroborated using the ER-negative breast cancer cell line MDA-MB-231, which has intrinsically high levels of Twist expression and is very aggressive in mice. In contrast, the ERpositive cell line, MCF-7, has very low levels of Twist and is less tumorigenic in severe combined immunodeficient mice. These results indicated that the upregulation of Twist, in combination with the downregulation of ER, could be a potential mechanism for the acquisition of an aggressive breast cancer phenotype. However, alternative mechanisms likely exist to silence ER expression in the absence of Twist in breast cell lines like MCF-10A and MDA-MB-468 (Pilat et al., 1998) . The importance of this finding is that loss of ER in breast cancer patients is indicative of a poor prognosis  Relative expression Twist regulates estrogen receptor-a expression in breast cancer F Vesuna et al Herynk and Fuqua, 2007) , and this loss of ER expression brought about by Twist may have implications for ERnegative and/or ER-resistant breast cancers. Twist exerts its negative regulatory activity at the transcriptional level by binding to E-boxes within promoter sequences. Overexpression of Twist showed a consistent 3-4 fold repression in promoter assays, indicating that Twist is a transcriptional repressor of ER expression. In vivo, each of the 26 putative Twistbinding sites may work independently or in some concerted fashion to downregulate the expression of ER. We confirmed the specificity of Twist binding to the ER promoter by employing Twist bHLH deletion mutants in promoter assays. This indicated that Twist binding to the ER promoter is abrogated once the functional helix-loop-helix domain is excised from Twist. ChIP, using the Twist-positive cell lines MCF-7/Twist and MDA-MB-231, confirmed that Twist binds in vivo to the ER promoter. The binding of Twist to the ER promoter in MDA-MB-231 cells provided further evidence that the downregulation of ER by Twist is a possible functional mechanism for the generation of ER negativity in Twist-positive breast cells.
A functional hallmark of ER-negative cells is the ability to proliferate without estrogen stimulation and the propensity for hormone resistance Herynk and Fuqua, 2007) . Significantly, Twist cells were able to grow without estrogen both in vitro and in vivo. They were also resistant to the selective estrogen receptor modulator, tamoxifen, and the selective estrogen receptor downregulator, fulvestrant, in vitro without significant G1 arrest compared with the Twist-negative parental MCF-7 cells. Moreover, Twist tumors were unaffected by tamoxifen treatment. These experiments strongly indicated that Twist expression caused hormone independence in breast cancer cells that possibly led to hormone resistance.
VV and PS area product of tumors have been utilized as surrogate markers for angiogenesis in tumors (Bikfalvi and Bicknell, 2002; Mironchik et al., 2005) . We observed that the intratumoral distribution pattern of VV and PS in MCF-7/Twist xenografts (without estrogen) was quite different from that in MCF-7/Twist (with estrogen). In the absence of estrogen, VV and PS were high in the periphery of the tumors, whereas, in the presence of estrogen, VV and PS they were increased both at the periphery and in the central region of the tumor. This could indicate that Twist drives vasculogenesis, independent of estrogen signaling. This would indicate that tumors expressing Twist are more likely to be aggressive, invasive and ultimately more metastatic due to the welldeveloped vasculature. This is in accord with earlier work showing that Twist is upregulated in breast cancers and is a down-regulator of E-cadherin Vesuna et al., 2008) . However, the higher VV and PS in the estrogen-supplemented tumors could possibly be ascribed to increased VEGF expression that is directly driven by estrogen (Sengupta et al., 2003) .
Mechanistically, we demonstrated that Twist interacts with DNMT3B and HDAC1 at the ER promoter. The recruitment of DNMT3B leads to de novo hypermethylation, whereas HDAC1 causes histone deacetylation, eventually leading to transcriptionally silenced chromatin (Figure 7) . We were able to reverse this state Figure 7 A model for the regulation of ER by Twist. A proposed model depicting the normal, active state of transcription with unmethylated promoter DNA and acetylated chromatin, leading to an ER-positive, hormone-sensitive state. On binding to its target E-boxes, Twist recruits HDAC1 that deacetylates histone proteins and leads to compaction of chromatin. Twist (with HDAC1) also interacts with DNMT3B at the E-boxes, which causes de novo methylation of the promoter area. Together with other, as yet unknown co-factors, Twist binding eventually leads to a repressive state of transcription that ultimately culminates in the shutting down of ER transcription.
Twist regulates estrogen receptor-a expression in breast cancer F Vesuna et al using the methylation inhibitor, AZA, and the HDAC inhibitor, VPA. Thus, we have presented the first evidence indicating that Twist can regulate ER expression by inducing promoter methylation and chromatin remodeling, in addition to transcriptional repression. Next, we directly targeted Twist with a lentivirusmediated downregulation strategy. We saw a greater change in the expression of ER than Twist. However, the expression of ER was only partially functional (B10%) compared with MCF-7, as seen by ERE binding assays. This could be attributed to factors such promoter methylation and chromatin deacetylation, which we have characterized earlier. The reactivation of ER by downregulating Twist expression may be of relevance in patients, as 1-10% of breast tumor cells producing ER are clinically responsive to tamoxifen treatment (Harvey et al., 1999) . Our data indicated that re-expression of ER is possible by the use of methylation inhibitors in Twistoverexpressing cells. The fact that an oncogene Twist is contributing to these epigenetic changes is a novel discovery and would indicate that the use of epigenetic therapy might be beneficial for patients with either estrogen-refractory disease or ER-negative breast cancer.
Twist expression is increased in high-grade human breast tumors and a high percentage of these are ERnegative . We have observed similar results in breast cancer patient microarrays that were available from other studies which showed a significant negative correlation between Twist and ER expression. The overexpression of Twist may provide a mechanistic link between the development of aggressive breast cancer and the loss of ER expression, and may provide a means by which to elucidate the ontogeny of ER-negative and/or estrogen-resistant breast cancers (Figure 7) . In summary, our results demonstrate an alternative mechanistic explanation for the loss of ER expression, in breast tumors, which supplements promoter methylation and de-acetylation. The loss of ER expression brought about by Twist has important implications with respect to breast cancer treatment in that Twist-overexpressing cells can proliferate in the absence of estrogen, as well as in the presence of the anti-estrogens, tamoxifen and fulvestrant. It may be possible to reverse the downregulation of ER by treating ER-negative tumors with a combination of Twist shRNA, methylation inhibitors, and HDAC inhibitors that would lead to a rescue of ER expression and a reversal of the ER negative phenotype. This could contribute to clearing the current roadblock of hormone independence and resistance to anti-hormonal treatment in the treatment of ER-negative breast cancer.
Materials and methods
Cell culture MCF-7, MDA-MB-231 and T-47D cell lines were obtained from American Type Tissue Collection (Manassas, VA, USA) and maintained as instructed. Production of the stable Twist-overexpressing cell line, MCF-7/Twist, has been described earlier Vesuna et al., 2009 ). For experi-ments involving hormone independence and anti-estrogen resistance, MCF-7 and MCF-7/Twist cells were plated at 500 000 cells per 100 mm dish in complete media. The following day, media was replaced by phenol-red free minimal essential media containing 5% CSS, and the cells were allowed to grow for 2 days. On the third day, media was replaced with complete minimal essential media (control), and phenol-red free-minimal essential media/5% CSS (hormone independence). For anti-estrogen treatment, phenol-red free-minimal essential media/5% CSS media was supplemented with 1 mM 4hydroxytamoxifen (tamoxifen) or 1 nM fulvestrant. Three days following drug treatment, the cells were harvested and fixed in 70% ethanol overnight. Cell cycle analysis was performed by laser scanning cytometry on a FacScan I (BD Biosciences, San Jose, CA, USA). Independent experiments were repeated four times. Data was analyzed using FlowJo (Tree Star Inc., Ashland, OR, USA) and ModFit LT 2.0 software (Verity House Software, Topsham, ME, USA).
Promoter analysis
Cloning of the ER promoter and the Twist deletion constructs has been described elsewhere (El Ghouzzi et al., 2000; deGraffenried et al., 2002) . The ER promoter constructs were transiently transfected (TransIT-LT1, Mirus Bio Corporation, Madison, WI, USA) along with the Twist expression constructs in the ER-positive breast cancer cell line, MCF-7. An enhanced green fluorescent protein expression plasmid pEGFP-N1 (Clontech, Mountain View, CA, USA) was used to determine transfection efficiency .
ChIP
ChIP was performed as described (Cell Signaling), with primers covering the entire region of the ER promoter. Primer sequences are listed in Supplementary data.
Methylation assays MCF-7, MCF-7/Twist, and MDA-MB-231 cells were grown to 70% confluence and DNA was extracted according to the manufacturer's protocol (Qiagen, Valencia, CA, USA). Subsequently, the DNA was processed for bisulfite treatment (Zymo Research, Orange, CA, USA). Bisulfite-treated DNA was PCR amplified using primers that amplify a 110-bp region around the Not I site of the CpG island in the first ER exon (O'Doherty et al., 2002) . Primer sequences are listed in Supplementary data.
Methylation inhibitor and HDAC inhibitor treatment
For demethylation treatment, cells were grown to 40-50% confluence in six-well plates and treated with 1 mM AZA for 3 days. At the end of this period, DNA was isolated and processed for demethylation studies by mold-specific-qPCR. Total proteins were extracted and immunoblotted to analyze the effect of demethylation on ER expression. Cells were treated with the HDAC inhibitor, VPA, at 10 mM concentration for 3 days and processed similarly.
Animal studies
Mice were anesthetized with acepromazine (62.5 mg/kg) and xylazine (6.5 mg/kg) or ketamine (100 mg/kg) and xylazine (10 mg/kg) in saline administered intraperitoneally for xenograft implantation procedures. Mice were orthotopically injected in the breast with 2 Â 10 6 MCF-7/Twist or control MCF-7 cells in 100 ml sterile complete media in the second mammary fat pad. A total of 15 female mice were injected with MCF-7/Twist cells and five female mice were injected with control MCF-7 cells. Estradiol pellets were 90-day slow release Twist regulates estrogen receptor-a expression in breast cancer (0.18 mg/pellet, Innovative Research of America, Sarasota, FL, USA) and tamoxifen pellets were 60-day slow release (5 mg/ pellet, IRA). All animal experiments were done under Institutional Animal Care and Use Committee guidelines established at the Johns Hopkins University School of Medicine.
Measurement of VV and PS area products
The measurement of VV and PS has been described in detail elsewhere (Bhujwalla et al., 2001; Mironchik et al., 2005) . Three-dimensional images were drawn for all the 17 mice (MCF-7 [ þ E2] n ¼ 5, MCF-7/Twist [ þ E2] n ¼ 6, MCF-7/ Twist [ÀE2] n ¼ 6), and the images presented are representative of each group. The parameters were eight slices, 1 mm slice thickness, field of view ¼ 32 mm, eight scans, and 0.25 mm in-plane spatial resolution.
Twist and ER mRNA expression levels in human breast cancers Frozen breast cancer samples, controlled for adequate tumor content (over 80%) by laser capture dissection, were obtained from the University Medical Center, Utrecht, The Netherlands. Total RNA was isolated using Trizol, reverse-transcribed using SuperScript III (Invitrogen, Carlsbad, CA, USA), and quantitative real-time PCR amplified. Expression values were normalized with the 36B4 gene.
Statistical analysis
Data was analyzed by an independent, two-sided Student's T-test. Statistics with respect to VV and PS area were performed by Scheffe's test. We examined the correlation in normalized (to normal breast tissue) expression between TWIST and ER genes, overall, and within each grade, using the non-parametric, Spearman's rank test. For all analysis, P-values below 0.05 were considered significant. In all figures, (*) denotes Po0.05, (**) denotes Po0.005, and (***) denotes Po0.0005.
